REVIEW

Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma

ORIGINAL ARTICLE

Clinical and Translational Research

Autophagy-related long non-coding RNA prognostic model predicts prognosis and survival of melanoma patients

Identification of circ_0000375 and circ_0011536 as novel diagnostic biomarkers of colorectal cancer
Yin TF, Du SY, Zhao DY, Sun XZ, Zhou YC, Wang QQ, Zhou GYJ, Yao SK

Retrospective Study

Echocardiography in the diagnosis of Shone’s complex and analysis of the causes for missed diagnosis and misdiagnosis
Li YD, Meng H, Pang KJ, Li MZ, Xu N, Wang H, Li SJ, Yan J

Predictors and prognostic impact of post-operative atrial fibrillation in patients with hip fracture surgery
Bae SJ, Kwon CH, Kim TY, Chang H, Kim BS, Kim SH, Kim HJ

Added value of systemic inflammation markers for monitoring response to neoadjuvant chemotherapy in breast cancer patients
Ke ZR, Chen W, Li MX, Wu S, Jin LT, Wang TJ

Washed microbiota transplantation reduces serum uric acid levels in patients with hyperuricaemia
Cai JR, Chen XW, He YJ, Wu B, Zhang M, Wu LH

Clinical Trials Study

Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma

META-ANALYSIS

Effect of enhanced recovery after surgery on inflammatory bowel disease surgery: A meta-analysis
Peng D, Cheng YX, Tao W, Tang H, Ji GY

Accuracy of ultrasound elastography for predicting breast cancer response to neoadjuvant chemotherapy: A systematic review and meta-analysis
Chen W, Fang LX, Chen HL, Zheng JH
## Contents

**World Journal of Clinical Cases**

Thrice Monthly Volume 10 Number 11 April 16, 2022

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3449</td>
<td>Association of chronic obstructive pulmonary disease with mild cognitive impairment and dementia risk: A systematic review and meta-analysis</td>
<td>Zhao LY, Zhou XL</td>
</tr>
<tr>
<td>3472</td>
<td>Difference and similarity between type A interrupted aortic arch and aortic coarctation in adults: Two case reports</td>
<td>Ren SX, Zhang Q, Li PP, Wang XD</td>
</tr>
<tr>
<td>3478</td>
<td>Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report</td>
<td>Huang KK, Han SS, He LY, Yang LL, Liang BY, Zhen QY, Zhu ZB, Zhang CY, Li HY, Lin Y</td>
</tr>
<tr>
<td>3485</td>
<td>Unusual glomus tumor of the lower leg: A case report</td>
<td>Wang HY, Duan P, Chen H, Pan ZY</td>
</tr>
<tr>
<td>3490</td>
<td>Pulmonary <em>Cladosporium</em> infection coexisting with subcutaneous <em>Corynespora cassiicola</em> infection in a patient: A case report</td>
<td>Wang WY, Luo HB, Hu JQ, Hong HH</td>
</tr>
<tr>
<td>3496</td>
<td>Preoperative diagnosis and management of breast ductal carcinoma <em>in situ</em> arising within fibroadenoma: Two case reports</td>
<td>Wu J, Sun KW, Mo QP, Yang ZR, Chen Y, Zhong MC</td>
</tr>
<tr>
<td>3505</td>
<td>Reconstruction of complex chest wall defects: A case report</td>
<td>Huang SC, Chen CY, Qiu P, Yan ZM, Chen WZ, Liang ZZ, Luo KW, Li JW, Zhang YQ, Huang BY</td>
</tr>
<tr>
<td>3511</td>
<td>Young children with multidrug-resistant epilepsy and vagus nerve stimulation responding to perampanel: A case report</td>
<td>Yang H, Yu D</td>
</tr>
<tr>
<td>3541</td>
<td>Severe gastric insufflation and consequent atelectasis caused by gas leakage using AIR-Q laryngeal mask airway: A case report</td>
<td>Zhao Y, Li P, Li DW, Zhao GF, Li XY</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>3547</td>
<td>Hypereosinophilic syndrome presenting as acute ischemic stroke, myocardial infarction, and arterial involvement: A case report</td>
<td>Sun RR, Chen TZ, Meng M</td>
</tr>
<tr>
<td>3553</td>
<td>Cytochrome P450 family 17 subfamily A member 1 mutation causes severe pseudohermaphroditism: A case report</td>
<td>Gong Y, Qin F, Li WJ, Li LY, He P, Zhou XJ</td>
</tr>
<tr>
<td>3573</td>
<td>Qingchang decoction retention enema may induce clinical and mucosal remission in left-sided ulcerative colitis: A case report</td>
<td>Li PH, Tang Y, Wen HZ</td>
</tr>
<tr>
<td>3587</td>
<td>Ultrasound-guided local ethanol injection for fertility-preserving cervical pregnancy accompanied by fetal heartbeat: Two case reports</td>
<td>Kakinuma T, Kakinuma K, Matsuda Y, Ohwada M, Yanagida K, Kaijima H</td>
</tr>
<tr>
<td>3593</td>
<td>Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report</td>
<td>Wei HP, Mao J, Hu ZL</td>
</tr>
<tr>
<td>3601</td>
<td>Del(5q) and inv(3) in myelodysplastic syndrome: A rare case report</td>
<td>Liang HP, Luo XC, Zhang YL, Liu B</td>
</tr>
<tr>
<td>3609</td>
<td>Papillary thyroid microcarcinoma with contralateral lymphatic skip metastasis and breast cancer: A case report</td>
<td>Ding M, Kong YH, Gu JH, Xie RL, Fei J</td>
</tr>
<tr>
<td>3615</td>
<td>Contrast-enhanced ultrasound manifestations of synchronous combined hepatocellular-cholangiocarcinoma and hepatocellular carcinoma: A case report</td>
<td>Gao L, Huang JY, Lu ZJ, Lu Q</td>
</tr>
<tr>
<td>3624</td>
<td>Thyrotoxicosis after a massive levothyroxine ingestion: A case report</td>
<td>Du F, Liu SW, Yang H, Duan RX, Ren WX</td>
</tr>
<tr>
<td>3630</td>
<td>Pleomorphic adenoma of the left lacrimal gland recurred and transformed into myoepithelial carcinoma after multiple operations: A case report</td>
<td>Huang WP, Li LM, Gao JB</td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial Board Member of World Journal of Clinical Cases, Chi-Yuan Yeh, MD, PhD, Assistant Professor, Chief Doctor, radiation oncology, Tungs' Taichung MetroHarbor Hospital, Taichung 43503, Taiwan.
peteryeh46@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING
The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2021 Edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJCC as 1.337; IF without journal self-cites: 1.301; 5-year IF: 1.742; Journal Citation Indicator: 0.33; Ranking: 119 among 169 journals in medicine, general and internal; and Quartile category: Q3. The WJCC’s CiteScore for 2020 is 0.8 and Scopus CiteScore rank 2020: General Medicine is 493/793.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Hua-Ge Yu; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
World Journal of Clinical Cases

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

EDITORS-IN-CHIEF
Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Juhn Hyeon Ku

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE
April 16, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Washed microbiota transplantation reduces serum uric acid levels in patients with hyperuricaemia

Jin-Rong Cai, Xin-Wen Chen, Yu-Jian He, Bin Wu, Min Zhang, Li-Hao Wu

Abstract

BACKGROUND

Previous studies have found that hyperuricaemia (HUA) is closely related to intestinal flora imbalance.

AIM

The current study investigated the effects and safety of washed microbiota transplantation (WMT) on serum uric acid (SUA) levels in different populations.

METHODS

A total of 144 patients who received WMT from July 2016 to April 2020 in the First Affiliated Hospital of Guangdong Pharmaceutical University and had SUA data before treatment were selected. Changes in SUA levels before and after treatment were retrospectively reviewed based on short-term and mid-term effects of WMT regimens. SUA levels measured in the last test within 3 mo after the first WMT represented the short-term effect, and SUA levels measured in the last test within 3-6 mo after the first WMT represented the mid-term effect. The patients were divided into an HUA group (SUA > 416 μM) and a normal uric acid (NUA) group (SUA ≥ 202 μM to ≤ 416 μM) based on pretreatment SUA levels.

RESULTS
Average short-term SUA levels in the HUA group decreased after WMT (481.00 ± 99.85 μM vs 546.81 ± 109.64 μM, n = 32, P < 0.05) in 25/32 patients and returned to normal in 10/32 patients. The short-term level of SUA reduction after treatment moderately correlated with SUA levels before treatment (r = 0.549, R² = 0.300, P < 0.05). Average SUA levels decreased after the first and second courses of WMT (469.74 ± 97.68 μM vs 540.00 ± 107.16 μM, n = 35, and 465.57 ± 88.88 μM vs 513.19 ± 78.14 μM, n = 21, P < 0.05). Short-term and mid-term SUA levels after WMT and SUA levels after the first, second and third courses of WMT were similar to the levels before WMT in the NUA group (P > 0.05). Only 1/144 patients developed mild diarrhea after WMT.

**CONCLUSION**

WMT reduces short-term SUA levels in patients with HUA with mild side effects but has no obvious effect on SUA levels in patients with NUA.

**Key Words:** Washed microbiota transplantation; Hyperuricaemia; Intestinal flora; Effect; Safety;

Retrospective study

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** In this study, we demonstrate that washed microbiota transplantation (WMT) can lower serum uric acid (SUA) levels in patients with hyperuricaemia in the short term with only mild side effects but that WMT has no obvious effect on the SUA levels of people with normal uric acid levels.

**Citation:** Cai JR, Chen XW, He YJ, Wu B, Zhang M, Wu LH. Washed microbiota transplantation reduces serum uric acid levels in patients with hyperuricaemia. *World J Clin Cases* 2022; 10(11): 3401-3413

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i11/3401.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i11.3401

**INTRODUCTION**

Nutrition-related diseases caused by changes in people’s diet are gradually increasing, and hyperuricaemia (HUA) has gradually developed into a global public health problem. HUA is a common disease in China. The prevalence of HUA in the Chinese population is 13%[1]. HUA is a metabolic syndrome related to obesity, insulin resistance, diabetes, coronary artery disease and hypertension, but it is also a pathological state that causes uric acid (UA) crystal deposition in bones, joints and kidneys, which may lead to gout, uric acid nephropathy[2,3].

The traditional treatment methods for HUA include maintaining a healthy lifestyle, UA-lowering drugs, alkalizing urine, and traditional Chinese medicine. Existing drugs for the treatment of HUA include xanthine oxidase inhibitors (allopurinol) to inhibit UA production, benz bromarone, which promotes UA excretion, and UA enzymes that promote UA decomposition[4,5]. However, these drugs have adverse reactions, such as gastrointestinal discomfort, diarrhoea, and rash, and some patients have poor tolerance. Patients also need to take drugs regularly for a long time, which causes a long-term burden for patients and their families because the existing UA-lowering drugs are associated with a withdrawal and rebound phenomenon[4,5]. Due to the limitations of drug use, novel therapeutic approaches are needed in the treatment of HUA.

The functional status of the intestines and kidneys is critical to the metabolism of UA. The daily production and excretion of UA in the human body is 600-700 mg. Approximately two-thirds of this amount is excreted by the kidneys, and one-third is excreted through the intestines. The intestinal pathway compensates in cases of renal damage and becomes the main pathway for urate elimination[6]. The imbalance between probiotics and pathogenic bacteria affects the expression of intestinal tight junction proteins, which increases the permeability of the intestinal mucosa barrier, leads to gut-derived lipopolysaccharide (LPS) translocation and causes kidney damage via blood circulation. These changes induce renal UA excretion disorder, reduce UA excretion and increase SUA (SUA) levels[7,8]. The intestinal flora also regulates adenosine triphosphate-binding cassette superfamily G member 2 (ABCG2), solute carrier family 2 member 9 (SLC2A9) and other UA transporters of the intestinal epithelium[9,10].

Faecal microbiota transplantation (FMT) recently emerged as a treatment strategy for HUA. FMT relate to the transplantation of the functional flora of a healthy individual into the gastrointestinal tract of a patient to establish a new intestinal microbiota for the treatment of intestinal and extraintestinal diseases. FMT technology was first used for treating refractory *Clostridium difficile* infection in 2013[11]. FMT also aids in inducing the remission of ulcerative colitis and improving hepatic encephalopathy and...
insulin sensitivity[12-14]. Washed microbiota transplantation (WMT), the generation of bacterial solutions via automatic purification systems, is respected in clinic. WMT reduces the adverse events caused by traditional faecal suspension preparations and greatly improves the treatment efficacy[15,16].

Previous studies have found that HUA is closely associated with an intestinal flora imbalance[17,18]. Manipulation of gut dysbiosis with probiotics relieves fructose-induced hyperuricaemia in mice and enhances intestinal barrier function[19]. A pilot study[20] found that all patients (n = 11) exhibited a reduction in SUA levels on day 28 post-FMT (P < 0.05). Our study expanded the sample size to retrospectively examine the short-term and mid-term effects and safety of WMT on SUA levels in patients with HUA and normal UA (NUA) levels.

MATERIALS AND METHODS

Participants
A total of 144 patients who received WMT treatment from July 2016 to April 2020 in the First Affiliated Hospital of Guangdong Pharmaceutical University and had SUA data before treatment were selected. All Patients in this study provided informed consent. Patients who received WMT treatment were divided into an HUA group and an NUA group based on their SUA levels before treatment. The inclusion criterion for the HUA group was an SUA ≥ 202 μM to ≤ 416 μM. The inclusion criterion for the NUA group was an SUA ≥ 202 μM to ≤ 416 μM.

Inclusion and exclusion criteria
Patients included in the study met the following criteria: (1) Aged 18-85 years; (2) received WMT treatment; and (3) had SUA data before and after treatment (Figure 1). The following exclusion criteria were used: (1) Gastrointestinal infection, cardiopulmonary failure or serious liver and kidney diseases; (2) pregnancy; (3) malignant tumours; (4) rejection to transendoscopic enteral tubing; (5) rejection or failure to complete the follow-ups; and (6) a high-purine diet.

WMT
All the patients were treated with WMT. Mixed multi-donor faeces were used as the source of the bacterial suspension for WMT. Healthy young men aged 18-25 years was one of requirements of the donors. The donors underwent health examinations to exclude metabolic diseases, genetic diseases, infectious diseases, digestive tract diseases, malignant tumours, and other associated diseases. The donors did not take antibiotics or drugs that affected alimentary canal dynamics and/or caused gut microecological disorders in the previous 3 mo. Utilizing an automatic purification system (GenFMTer; FMT Medical, Nanjing, Jiangsu Province, China), bacterial solution (200 mL) was isolated and injected into the sick’s gut through the lower or middle alimentary canal within 30 min. Two transplantation routes were available for use. One route was the middle alimentary canal route in which transendoscopic enteral tubing was placed in the jejunum under gastroscopy, and proton pump inhibitors were administered intravenously 1 h before the injection. This procedure was performed to lower the inactivation of bacteria when moving through the stomach. Metoclopramide hydrochloride (10 mg) was injected intramuscularly to decrease side effects, like abdominal distension or vomiting, resulted from stimulus of the digestive tract by the fresh faecal liquid. The sick was placed in a sitting position during injection of the fresh faecal liquid. The injection procedure was mild and slow, and needed at least 30 min for 200 mL of the fresh faecal liquid. After the injection, the patient sustained standing or seated not less than 2 h. The other method was the lower alimentary canal route in which transendoscopic enteral tubing was placed into the caecum by means of colonoscopy. During injection of the fresh faecal liquid, the sick was placed in the right sided position, and this process lasted for 30 min. Completed this procedure, the sick rested in the right sided position for at least 2 h. One course was administered once daily for 3 d. Four courses were administered at one course per month in the first month, second month, third month, and sixth month.

Outcome measures
The main outcome was the changes in SUA levels before and after WMT treatment. The SUA measured in the last test within 3 mo after the first WMT represented the short-term effect, and the SUA measured in the last test within 3-6 mo after the first WMT was the mid-term effect. The secondary outcomes included the WMT course and occurrence of adverse events (AEs) after WMT. In accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, We graded the AEs and classified the relationship between AEs and WMT as unrelated and possibly, probably and definitely related.

Statistical analysis
Statistical product and service solutions version 26.0 were used for data analyses. Categorical data are expressed as the frequency and percentage, and numerical data are expressed as the mean ± SD.
Cai JR et al. WMT reduces SUA levels

Figure 1 Flow chart of patient inclusion for analysis effects of washed microbiota transplantation on serum uric acid levels. A: Flow chart of patient inclusion for analysis of the short-term and mid-term effects of washed microbiota transplantation (WMT) on serum uric acid (SUA) levels; B: Flow chart of patient inclusion for analysis of the effects of the course of WMT on SUA levels. HUA: Hyperuricaemia; NUA: Normal uric acid; SUA: Serum uric acid; WMT: Washed microbiota transplantation.

RESULTS

Baseline data of the patients

Most of the patients were not treated with WMT due to HUA (Table 1). The patients received different
deviation. If a normal distribution was observed, Student’s t test was used for comparison between
groups. Otherwise, the Wilcoxon signed rank test was used. Differences were defined as statistically
significant when \( P < 0.05 \).

DOI: 10.1299/wjcc.v10.i11.3401 Copyright © The Author(s) 2022.
Table 1 Main diagnosis of 144 patients receiving washed microbiota transplantation

<table>
<thead>
<tr>
<th>Main diagnosis</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irritable bowel syndrome</td>
<td>32 (22.22)</td>
</tr>
<tr>
<td>Functional constipation</td>
<td>22 (15.28)</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>14 (9.72)</td>
</tr>
<tr>
<td>Gastroesophageal reflux disease</td>
<td>14 (9.72)</td>
</tr>
<tr>
<td>Nonalcoholic fatty liver disease</td>
<td>11 (7.64)</td>
</tr>
<tr>
<td>Childhood autism</td>
<td>9 (6.25)</td>
</tr>
<tr>
<td>Functional enteropathy</td>
<td>5 (3.47)</td>
</tr>
<tr>
<td>Functional diarrhea</td>
<td>5 (3.47)</td>
</tr>
<tr>
<td>Gout</td>
<td>5 (3.47)</td>
</tr>
<tr>
<td>Cirrhosis after hepatitis</td>
<td>3 (2.08)</td>
</tr>
<tr>
<td>Functional abdominal pain syndrome</td>
<td>3 (2.08)</td>
</tr>
<tr>
<td>Radiation colitis</td>
<td>2 (1.39)</td>
</tr>
<tr>
<td>Chronic viral hepatitis B</td>
<td>2 (1.39)</td>
</tr>
<tr>
<td>Other</td>
<td>16 (11.11)</td>
</tr>
</tbody>
</table>

short- and mid-term courses of WMT in the HUA group and the NUA group (Table 2).

Analysis of the short-term and mid-term effects of WMT on SUA levels

The short-term average SUA level after WMT treatment in the HUA group was lower than that before treatment (481.00 ± 99.85 vs 546.81 ± 109.64 μM, n = 32, P < 0.05; Table 3 and Figure 2A). The mid-term average SUA level after WMT treatment was lower than that before treatment, but the difference was not statistically significant (483.00 ± 101.21 vs 504.00 ± 100.30 μM, n = 9, P > 0.05; Table 3 and Figure 2A). The mid-term average SUA level after WMT treatment decreased compared with the short-term SUA level after treatment, but the difference was not statistically significant (485.88 ± 107.80 vs 528.12 ± 111.89 μM, n = 8, P > 0.05; Table 3 and Figure 2A). The average short-term and mid-term SUA levels after treatment in the NUA group were similar to the levels before treatment (P > 0.05; Table 3 and Figure 2B).

SUA levels decreased in the short term after treatment in 25 patients in the HUA group (78.12%), and SUA levels returned to normal in 10 patients (31.25%). A total of 55.56% (5/9) of patients had a decrease in SUA levels in the mid-term after treatment, and the SUA levels of 22.22% (2/9) of these patients returned to normal (Figure 3).

Correlation analysis between the short-term SUA reduction level after WMT treatment and SUA before treatment

The relationship between the short-term SUA reduction level after WMT treatment and the SUA level before treatment in the HUA group showed r = 0.549 and R² = 0.300 (P < 0.05), which suggested that the short-term SUA reduction level after WMT treatment and the SUA level before treatment were moderately correlated (Figure 4).

Analysis of the effects of the course of WMT on SUA levels

The average SUA level of the patients in the HUA group decreased after the first course of WMT compared with that before treatment (469.74 ± 97.68 vs 540.00 ± 107.16 μM, n = 35, P < 0.05; Table 4 and Figure 5A). The average SUA level of the patients in the HUA group was lower after the second course of WMT than before treatment (465.57 ± 88.88 vs 513.19 ± 78.14 μM, n = 21, P < 0.05; Table 4 and Figure 5A). The average SUA level of the patients in the HUA group after the third course of WMT was decreased compared with that before treatment, but the difference was not statistically significant (417.36 ± 92.84 vs 526.73 ± 111.30 μM, n = 11, P > 0.05; Table 4 and Figure 5A). The average SUA level of the patients in the NUA group (n = 100) after receiving different courses of WMT was similar to that before treatment (P > 0.05; Table 4 and Figure 5B).

Analysis of the short-term and mid-term effects of WMT on serum creatinine levels

The average short-term and mid-term serum creatinine levels after treatment were similar to those before treatment in both groups (P > 0.05; Table 5).
Table 2 Short-term (within 3 mo) and mid-term (within 3-6 mo) washed microbiota transplantation treatment courses in the hyperuricaemia group and normal uric acid group

<table>
<thead>
<tr>
<th>Time</th>
<th>Group</th>
<th>n</th>
<th>1 course</th>
<th>2 courses</th>
<th>3 courses</th>
<th>4 courses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term</td>
<td>HUA group</td>
<td>32</td>
<td>1</td>
<td>21</td>
<td>10</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>NUA group</td>
<td>74</td>
<td>1</td>
<td>51</td>
<td>22</td>
<td>-</td>
</tr>
<tr>
<td>Mid-term</td>
<td>HUA group</td>
<td>9</td>
<td>-</td>
<td>1</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>NUA group</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>15</td>
<td>5</td>
</tr>
</tbody>
</table>

HUA: Hyperuricaemia; NUA: Normal uric acid.

Table 3 Changes in short-term (within 3 mo) and mid-term (within 3-6 mo) serum uric acid levels before and after washed microbiota transplantation treatment

<table>
<thead>
<tr>
<th>Group</th>
<th>SUA levels (μM) Before treatment</th>
<th>Short-term effect after treatment</th>
<th>P value</th>
<th>SUA levels (μM) Before treatment</th>
<th>Mid-term effect after treatment</th>
<th>P value</th>
<th>SUA levels (μM) Short-term effect after treatment</th>
<th>Mid-term effect after treatment</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUA group (n = 44)</td>
<td>546.81 ± 109.64 (n = 32)</td>
<td>481.80 ± 99.85 (n = 32)</td>
<td>0.001</td>
<td>504.0 ± 100.3 (n = 9)</td>
<td>483.00 ± 101.21 (n = 9)</td>
<td>0.596</td>
<td>528.12 ± 111.89 (n = 9)</td>
<td>485.88 ± 107.80 (n = 9)</td>
<td>0.276</td>
</tr>
<tr>
<td>NUA group (n = 100)</td>
<td>322.8 ± 52.0 (n = 74)</td>
<td>326.62 ± 63.30 (n = 74)</td>
<td>0.500</td>
<td>308.30 ± 70.28 (n = 20)</td>
<td>325.50 ± 101.03 (n = 20)</td>
<td>0.350</td>
<td>309.10 ± 68.32 (n = 20)</td>
<td>325.50 ± 101.03 (n = 20)</td>
<td>0.301</td>
</tr>
</tbody>
</table>

SUA: Serum uric acid; HUA: Hyperuricaemia; NUA: Normal uric acid.

Table 4 Changes in serum uric acid before and after treatment in patients receiving different courses of washed microbiota transplantation

<table>
<thead>
<tr>
<th>Group</th>
<th>SUA levels (μM) Before treatment</th>
<th>After first course of WMT</th>
<th>P value</th>
<th>SUA levels (μM) Before treatment</th>
<th>After second course of WMT</th>
<th>P value</th>
<th>SUA levels (μM) Before treatment</th>
<th>After third course of WMT</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUA group (n = 44)</td>
<td>540.00 ± 107.16 (n = 35)</td>
<td>469.74 ± 97.68 (n = 35)</td>
<td>0.001</td>
<td>513.19 ± 78.14 (n = 21)</td>
<td>465.57 ± 88.88 (n = 21)</td>
<td>0.026</td>
<td>526.73 ± 111.30 (n = 11)</td>
<td>417.36 ± 92.84 (n = 11)</td>
<td>0.101</td>
</tr>
<tr>
<td>NUA group (n = 100)</td>
<td>320.55 ± 52.73 (n = 77)</td>
<td>328.86 ± 71.91 (n = 77)</td>
<td>0.184</td>
<td>317.29 ± 57.44 (n = 51)</td>
<td>323.18 ± 68.06 (n = 51)</td>
<td>0.442</td>
<td>333.00 ± 55.49 (n = 27)</td>
<td>328.59 ± 73.52 (n = 27)</td>
<td>0.628</td>
</tr>
</tbody>
</table>

HUA: Hyperuricaemia; NUA: Normal uric acid; WMT: Washed microbiota transplantation.

Analysis of the safety of WMT
No serious adverse reactions occurred during WMT treatment in the 144 treated patients. Only one patient developed mild diarrhea during the second WMT treatment, which gradually returned to normal within 3 d. This AE was classified as possibly related to WMT.

DISCUSSION
HUA is closely related to intestinal flora imbalance. A bacterial disorder was observed in patients with HUA that manifested as an increase in the total count of aerobes, *Escherichia coli* and *Bacteroides* and a decrease in the number of *Lactobacillus* and *Bifidobacteria*.[17] The composition of the intestinal flora also changed in animal models of HUA caused by a high-fat diet, a high-glucose diet, a high-fructose diet, and a high-oxalic-acid diet.[18,21,22] Liu *et al*.[23] transplanted the faecal flora of HUA rats into recipient
Table 5 Changes in short-term (within 3 mo) and mid-term (within 3-6 mo) serum creatinine levels before and after washed microbiota transplantation treatment

<table>
<thead>
<tr>
<th>Group</th>
<th>SCR levels (μM) Before treatment</th>
<th>Short-term effect after treatment</th>
<th>P value</th>
<th>SCR levels (μM) Mid-term effect after treatment</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HUA group (n = 44)</td>
<td>73.00 ± 20.17 (n = 29)</td>
<td>72.07 ± 17.27 (n = 29)</td>
<td>0.575</td>
<td>68.44 ± 14.67 (n = 9)</td>
<td>0.798</td>
</tr>
<tr>
<td>NUA group (n = 100)</td>
<td>64.85 ± 13.74 (n = 73)</td>
<td>64.67 ± 13.22 (n = 73)</td>
<td>0.791</td>
<td>66.3 ± 14.6 (n = 20)</td>
<td>0.890</td>
</tr>
</tbody>
</table>

HUA: Hyperuricaemia; NUA: Normal uric acid.

Figure 2 Changes in short-term (within 3 mo) and mid-term (within 6 mo) serum uric acid levels. A: Hyperuricaemia group (n = 32) before and after washed microbiota transplantation (WMT) treatment. Short-term after treatment and before treatment: 481.00 ± 99.85 vs 546.81 ± 109.64 μM, P = 0.001. Mid-term after treatment and before treatment: 483.00 ± 101.21 vs 504.00 ± 100.30, P = 0.596. Short-term after treatment and mid-term after treatment: 485.88 ± 107.80 vs 528.12 ± 111.89, P = 0.276; B: Normal uric acid group (n = 100) before and after WMT treatment. Short-term after treatment and before treatment: 326.62 ± 63.30 vs 322.80 ± 52.00 μM, P = 0.500. Mid-term after treatment and before treatment: 325.50 ± 101.03 vs 308.30 ± 70.28, P = 0.350. Short-term after treatment and mid-term after treatment: 325.50 ± 101.03 vs 309.10 ± 68.32, P = 0.301.

DOI: 10.12998/wjcc.v10.i11.3401 Copyright © The Author(s) 2022.
Cai JR et al. WMT reduces SUA levels

**Figure 3** The number of cases serum uric acid level reduction after washed microbiota transplantation treatment in the hyperuricaemia group. A: The number of cases with short-term (within 3 mo) serum uric acid level reduction after washed microbiota transplantation (WMT) treatment in the hyperuricaemia (HUA) group; B: The number of cases with mid-term (within 6 mo) serum uric acid level reduction after WMT treatment in the HUA group.

Previous studies have shown that probiotics effectively treat HUA\[24,25\]. However, one study demonstrated that symbiotic and probiotic interventions had no effect on SUA levels after 12 wk of intervention\[26\]. A meta-analysis showed that UA levels were significantly increased in the intervention group compared to a control group\[27\].

These studies have clarified the differences in the intestinal flora between patients with HUA and healthy individuals, but controversy over the role of probiotics in reducing SUA remains. WMT significantly improves intestinal bacterial disorders and is currently recognized as the most effective method to restore the intestinal microecological balance. A pilot study\[20\] found that all patients \(n = 11\) had a reduction in SUA levels on day 28 post-FMT \((P < 0.05)\). However, this study did not examine the short- and mid-term effects of WMT on patients with NUA levels or the mid-term effect of WMT on patients with HUA and had a relatively small sample size.

The average SUA level in the HUA group decreased within 3 mo after WMT in our study \((P < 0.05)\). Short-term SUA levels decreased in 25 patients (78.12%) after treatment, and SUA levels returned to normal in 10 patients (31.25%). The mechanism of WMT treatment in the reduction of UA may involve...
two pathways, promotion of UA decomposition and excretion. The intestinal flora degrade UA into allantoin[28]. The intestinal flora also affect the metabolism of UA by regulating ABCG2, SLC2A9 and other UA transporters of the intestinal epithelium[9,10]. Some scholars[7,8] have hypothesised a “metabolic endotoxemia”, wherein changes in the structure of the intestinal flora can increase the permeability of the intestinal tract and cause microbial metabolites, such as endotoxins or LPS, to increase in the host circulatory system. LPS forms an immune complex with its receptor CD14, which is recognized by Toll-like receptor 4 on the surface of immune cells and causes kidney damage through blood circulation. These effects subsequently lead to renal UA excretion disorders and reduced UA excretion, which increase SUA levels. Wang et al[19] treated mice with fructose-induced HUA with isolated Lactobacillus brevis DM9218. The results showed that DM9218 decreased SUA levels, hepatic xanthine oxidase activity and liver LPS in fructose-fed mice. Diamine oxidase and endotoxin levels decreased after FMT in a clinical study (P < 0.05)[20]. Because our study was a retrospective study, further studies are needed to explore the mechanism of WMT reduction of SUA. The SUA levels of some patients in the HUA group did not decrease. The high SUA levels in these patients may not be the result of an intestinal flora imbalance, and WMT had no obvious effect, or it interfered with other factors, such as a high-purine diet. Therefore, we should clarify that the role of WMT in HUA results from different causes in further studies.

After WMT in the HUA group, SUA levels at the mid-term observation point were reduced compared with those before treatment and at the short-term observation point. However, there was no significant difference (P > 0.05). It may be associated with the small sample included in the mid-term observation. Alternatively, WMT may have no effect on mid-term SUA levels in HUA. Follow-up studies should further expand the sample size and extend follow-up time to clarify the mid-term and long-term effects of WMT treatment.

There was a difference in the number of courses of WMT in the evaluation of short-term and long-term effects (Table 2). Therefore, we further analysed the effect of WMT on SUA in different populations based on the number of treatment courses. After one and two courses of WMT in the HUA group, the average SUA level decreased (P < 0.05), which indicated that the first and second courses of WMT played a significant impact on reducing SUA levels in patients with HUA. After three courses, the average SUA level decreased compared with that before treatment, but the difference was not statistically significant (P > 0.05). This finding may be related to the small sample size or may suggest that the third course of WMT cannot reduce SUA levels. Follow-up researches with a larger sample capacity are needed to elucidate the effect on SUA level of the third course of treatment. Because of the limited number of patients in this study with complete UA data before treatment and after each treatment, it was difficult to further analyse the relationship between the number of courses of treatment and the effect of WMT. Future research should investigate the optimal course of treatment for HUA.

The average SUA level in the NUA group was similar to that before treatment, and the difference was not statistically significant. This finding suggests that WMT treatment does not interfere with normal UA metabolism. These results also provide evidence to support the safety of WMT treatment from the perspective of UA metabolism.

Figure 4 The linear relationship between the short-term (within 3 mo) uric acid reduction level after washed microbiota transplantation treatment and the serum uric acid level before treatment in the hyperuricaemia group (n = 32).
Figure 5 Changes in the serum uric acid level before and after different courses of washed microbiota transplantation. A: Hyperuricaemia group (n = 44). After the first course of washed microbiota transplantation (WMT) and before treatment: 469.74 ± 97.68 vs 540.00 ± 107.16, P = 0.001. After the second course of WMT and before treatment: 465.57 ± 88.88 vs 513.19 ± 78.14, P = 0.026. After the third course of WMT and before treatment: 417.36 ± 92.84 vs 526.73 ± 111.30, P = 0.101; B: Normal uric acid group (n = 100). After the first course of WMT and before treatment: 328.86 ± 71.91 vs 320.55 ± 52.73, P = 0.184. After the second course of WMT and before treatment: 323.18 ± 68.06 vs 317.29 ± 57.44, P = 0.442. After the third course of WMT and before treatment: 328.59 ± 73.52 vs 333 ± 55.49, P = 0.628. WMT: Washed microbiota transplantation.

The safety of WMT is noteworthy. Only one patient developed mild diarrhea during the second WMT treatment, which gradually returned to normal within 3 d. A systematic review analysed the FMT-related AEs reported in 129 studies worldwide from 2000 to 2020, and the results showed that the total incidence of FMT-related AEs was 19%[29]. The low number of adverse reactions in the current study may be related to the use of WMT instead of FMT or the small sample size. Due to the short follow-up time, the current study could not clarify the long-term safety of WMT for the treatment of HUA.

The current study also has the following limitations: (1) No analysis of the effects of WMT on the improvement of gout flares in people with HUA; (2) no placebo control group or UA-lowering drug group; and (3) a single-centre design, which may lead to regional and genetic background bias.
CONCLUSION

WMT reduces SUA levels of patients with HUA in the short term with mild side effects but has no obvious effect on the SUA level of patients with NUA.

ARTICLE HIGHLIGHTS

Research background
Hyperuricaemia (HUA) pathogenesis is closely associated with intestinal bacteria.

Research motivation
Current treatments for HUA have failed to obtained satisfactory clinical results.

Research objectives
To investigate the effect and safety of washed microbiota transplantation (WMT) on serum uric acid (SUA) levels in different populations.

Research methods
A total of 144 patients who received WMT from July 2016 to April 2020 in the First Affiliated Hospital of Guangdong Pharmaceutical University and had SUA data before treatment were selected. The changes in SUA levels before and after treatment were retrospectively reviewed. According to the pretreatment SUA level, the patients were divided into a hyperuricaemia group (HUA group: SUA > 416 μM) and a normal uric acid group (NUA group: SUA ≥ 202 μM to ≤ 416 μM). Statistical product and service solutions 26.0 was used to analyse the data.

Research results
The average short-term SUA levels in the HUA group decreased after WMT (481.00 ± 99.85 vs 546.81 ± 109.64 μM, n = 32, P < 0.05). The levels decreased in 25/32 patients and returned to normal in 10/32 patients. The short-term level of SUA reduction after treatment moderately correlated with the SUA levels before treatment (r = 0.549, R² = 0.300, P < 0.05). The average SUA levels decreased after the first and second courses of WMT (469.74 ± 97.68 vs 540.00 ± 107.16 μM, n = 35, 465.57 ± 88.88 vs 513.19 ± 78.14 μM, n = 21, P < 0.05). Short-term and mid-term SUA levels in the NUA group after WMT and SUA levels after the first, second and third courses of WMT were similar to those before WMT (P > 0.05). Only 1/144 patients developed mild diarrhoea after WMT.

Research conclusions
WMT can lower the SUA level in patients with HUA in the short term with mild side effects, but WMT has no obvious effect on the SUA level of patients with NUA.

Research perspectives
WMT may be a novel treatment for HUA.

ACKNOWLEDGEMENTS

We thank the information department and medical records room of the First Affiliated Hospital of Guangdong Pharmaceutical University for their help on data collection and patients follow-up from the bottom of our heart. We honestly acknowledge Zheng YM at the First Affiliated Hospital of Guangdong Pharmaceutical University for her guidance during the submission process. We truly thank Fu SL, Wang XH, Zhu JW and Guo JD at the Inner Mongolia Ewenki Autonomous Banner People’s Hospital for their help on patients follow-up. We also sincerely thank the patients for their enthusiastic participation in our study.

FOOTNOTES

Author contributions: Cai JR, Chen XW, He YJ and Wu B jointly analysed the data, wrote the manuscript, and contributed equally to this article; Zhang M provided statistical advice; Wu LH designed the study and revised the manuscript; all authors read and approved the manuscript.

Supported by the Innovation and Entrepreneurship Training Program for College Students of Guangdong Province, No. S201910573028.
REFERENCES


Ren KY, Yong CM, JIN YC, Cao B, Wei LZ. Analysis of intestinal flora in patients with hyperuricemia in Qindao District. *Zhongguo Yishi Zazhi* 2014; 16: 1649-1651, 1656


